Surgeries are being postponed because of a surgical gown shortage
When the patriarch of a Boston-area family was diagnosed with stage 3 pancreatic cancer, the family was told he needed to start treatment immediately.
Publication date: March 2020Source: Advances in Medical Sciences, Volume 65, Issue 1Author(s): Javad Masoumi, Abdollah Jafarzadeh, Hossein Khorramdelazad, Morteza Abbasloui, Jalal Abdolalizadeh, Najmeh JamaliAbstractApelin is an endogenous peptide, which is expressed in a vast board of organs such as the brain, placenta, heart, lungs, kidneys, pancreas, testis, prostate and adipose tissues. The apelin receptor, called angiotensin-like-receptor 1 (APJ), is also expressed in the brain, spleen, placenta, heart, liver, intestine, prostate, thymus, testis, ovary, lungs, kidneys, stomach, and adipose tissue. The apelin/APJ axis ...
Publication date: Available online 20 February 2020Source: European Journal of Surgical OncologyAuthor(s): Marcus Roalsø, Jan Rune Aunan, Kjetil SøreideAbstractIn order to provide optimal cancer care and prognostication, it is necessary to stage the disease. The 8th edition of the TNM-staging for exocrine pancreatic ductal adenocarcinoma (PDAC) system has refined size-based T-stages and number-based N-categories. However, several impediments to the value of this may exist. For one, even at small size (e.g.
Publication date: Available online 19 February 2020Source: European Journal of Surgical OncologyAuthor(s): Maximilian Weniger, Rainer C. Miksch, Patrick Maisonneuve, Jens Werner, Jan G. D’HaeseAbstractIntroductionSurgical resection improves survival in pancreatic ductal adenocarcinoma (PDAC) and adjuvant chemotherapy adds an additional survival-benefit. While surgical technique has improved in recent years, it remains unclear whether these improvements translate into a survival benefit independent of adjuvant chemotherapy. Thus, we aimed to clarify whether survival of patients who were treated with either Gemcitabine...
To develop a porcine model of pancreatic cancer, which can be used to test new locoregional therapies. Pigs have similar physiology, drug dosing, and immune response to humans (unlike mice and other small animals). Locoregional therapy in pigs can be performed using the same size catheters and devices as humans.
Treatment for locally advanced pancreatic cancer (LAPC) remains a challenge. As intra-arterial (IA) chemotherapy has become a first-line option for hepatic tumors, there is interest in such approach for LAPC, despite lack of tumor feeders precluding chemo-embolization. The use of a double balloon catheter (RenovoCath) to isolate the artery next to the tumor, followed by pressure mediated transarterial drug delivery, is being explored.
Pancreatic cancer is the fourth leading cause of cancer-related mortality with less than 8% 5-year survival rates. Knowledge on pathogenesis and tumor microenvironment of pancreatic cancer has advanced largely because of mice models; however, a mouse model is unsuitable for site selective delivery. The purpose of this study was to develop an orthotopic rat model of pancreatic cancer suitable to evaluate localized delivery of therapeutics
Conclusions: LTS is an innovative clinical parameter of toxicity burden, differential treatment-related TS in individual patient. LTS can evaluate pharmacogenomic biomarkers predictive relevance to select mGI patients fit for intensive treatments, at risk of limiting gastrointestinal toxicity.Trial Registrations: The trials were registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2007-004946-34, and Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2009- 016793-32.
Conditions: Pancreatic Cancer; Pancreatic Cyst Interventions: Other: Blood Sample collection; Other: Tissue sample collection; Other: Data collection Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); University of Florida; University of Miami Recruiting
Condition: Pancreatic Cancer Intervention: Combination Product: LUM Imaging System Sponsor: Lumicell, Inc. Not yet recruiting
Conditions: Locally Advanced Pancreatic Cancer; Irreversible Electroporation Intervention: Device: Irreversible electroporation (NanoKnife® ) Sponsor: University of Saskatchewan Not yet recruiting